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A window into the molecular
basis of human brain plasticity
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Cortical plasticity can be defined as the
process whereby brain cortex changes in
response to experience or environment.
This can be described at the anatomical,
physiological or behavioural level. It is a
topic of major importance to humans,
being critical to normal development and
learning. Clinically, cortical plasticity is part
of how patients with CNS disease show
behavioural recovery, respond to therapy or
learn to compensate.
The underlying basis of cortical plasticity
has been extensively investigated. Animal
studies have provided insights into the
cellular and molecular events essential for
these processes. For example, acquisition
of a new motor skill is accompanied by
changes in gene expression, growth factor
levels, neuronal morphology and more. In
humans, insights into underlying events
have largely been at the systems level, via
functional neuroimaging.
It is in this context that the report of
Cheeran et al. (2008) in this issue of The
Journal of Physiology provides welcomed
new insights into molecular correlates of
cortical plasticity in the human brain.
These authors used non-invasive methods
in healthy human subjects to characterize
the effects that a single nucleotide poly-
morphism in the gene for brain-derived
neurotrophic factor (BDNF) has on three
neurophysiological measures related to
cortical plasticity. For all three probes,
results converged on the finding that
plasticity is abnormal in the presence of this
polymorphism.
BDNF is the most abundant growth
factor in the human brain. A single
nucleotide change at codon 66, present
in one or both alleles in approximately
30% of people, results in the switch
of a single amino acid, from valine to
methionine. Significant changes in human
brain structure, function and behaviour
have been described in the presence of
this polymorphism, whether it occurs in
one or both of a subject’s BDNF alleles. A
landmark human study on this topic came
from Egan et al. (2003), who found that
the presence of the Val66Met polymorphism
was associated with poorer memory,
abnormal hippocampal activation with
functional MRI (fMRI) and neurochemical
deficiencies withMRI spectroscopy. Indeed,
a later study from this group (Hariri et al.
2003) found that 25% of the variance
in memory performance among healthy
human subjects could be explained by
the interaction between BDNF Val66Met
polymorphism status and hippocampal
response during a memory fMRI task.
Our group (Kleim et al. 2006) examined
motor maps in healthy subjects before
and after 30 min of training. Subjects
lacking the BDNF Val66Met polymorphism
showed the expected motor map expansion
with training, but subjects with the poly-
morphism in one or both alleles showed
little such plasticity. Cheeran et al. used
three separate protocols to provide further
insights into the effects of the BDNF
Val66Met polymorphism on cortical neuro-
physiology and plasticity in healthy human
subjects. These authors interpreted their
results as reflecting a BDNF effect on
long-term potentiation, a process of direct
relevance to numerous neurological and
psychiatric conditions.
Why might we care about the molecular
basis of cortical plasticity in humans?
Several possible reasons might be advanced.
First, greater insight into themolecular basis
of human cortical plasticity might provide
better insight into the pathophysiology of
human disease. This then sets the table for
improved prognosis and therapeutics (Floel
& Cohen, 2006). Two general examples
of this principle are the advances in
amyotrophic lateral sclerosis research upon
identification of a mutation of the free
radical metabolism enzyme CuZn-SOD
in selected families, and the improved
prognostic ability upon identification of
the BRCA1/BRCA2 gene in breast cancer.
Second, such studies might also provide
more precise means to identify biologically
distinct patient subgroups or to sharpen
entry criteria in order to reduce variance
in clinical trials. Third, molecular studies
in humans provide a means to validate
molecular findings from animal studies.
That is, we rely heavily on animal models
to develop new human therapeutics, and
in many conditions we draw conclusions
that push the limits of animal models.
Molecular measures have the potential to
increase the fidelity of comparisons between
human subjects and related animal models.
Fourth, molecular studies in humans have
the potential to provide insight into genetic
influences on brain function and behaviour,
a topic of increasing interest to fields from
neuropsychology of the healthy to clinical
pharmacogenomics.
Cortical plasticity subserves much of
human behaviour, and it is a key player
in the brain repair that underlies recovery,
or in some cases maintenance, of function
with neurological and psychiatric disease.
Molecular insights into the basis of cortical
plasticity in humans have the potential to
support advances of broad value, in health
and in sickness. For example, suchmeasures
might have prognostic value (Siironen et al.
2007), might be used to guide features of
therapy, or might even be the target of
a gene-based therapeutic intervention. In
addition, note that many growth factors
have endogenous biological activity in
multiple organ systems, and so insights
into the molecular science of growth factor
effects in the brain could have broad utility
in clinical medicine. By focusing on a
common polymorphism in a major brain
molecule, Cheeran et al. have moved us
closer towards these goals.
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